In Clinical & Translational Radiation Oncology, UMC Utrecht clinicians detail their SBRT of (ultra)central lung tumors experience with Elekta Unity. Findings suggest #MRgRT could enhance the distinction between OARs and target volumes near the mediastinum and enable ITV modification for each fx in response to

ESTRO invites visionary leaders in #radonc to apply for the position of Editor-in-Chief for Clinical & Translational Radiation Oncology.
🚀Leading Journal: close to 200 annual publications, Impact Factor: 4.7
🎯Responsibilities: Lead the strategic direction of the Journal.
✅Apply Now: bit.ly/4aNr1iQ

Publication alert in Clinical & Translational Radiation Oncology📣 #ProtonTherapy planning and image-guidance strategies within a randomized controlled trial for high-risk #ProstateCancer : ctro.science/article/S2405-…

Anne Vestergaard Morten Høyer @Alsner Lise Bentzen Stine Elleberg Petersen et. al.

Great to see the network meta analysis published in The Lancet Oncology

Remember the standard meta analysis from the same group is available for free in ctRO

Link here: ctro.science/article/S2405-…

ESTRO ACROP Guidelines on Prostate bed delineation. Proud to be part of this important publication !
doi.org/10.1016/j.ctro…

ESTRO Guideline on Prostate Bed Delineation for Postoperative Radiotherapy in #Prostate #Cancer , just published in Clinical & Translational Radiation Oncology and presented this morning at #ESTRO23 .
Access the article 👉 bit.ly/3Og8iUo

Guys, remember to publish all your good science at ctRO!

CtRO.science

Cc Pierre Blanchard, MD ESTRO

#openaccess

Is single fraction the future of stereotactic #radiotherapy ?

My colleague Mario Terlizzi and others at Gustave Roussy have tried to identify pros/cons & perspectives.

Full text #OpenAccess at Clinical & Translational Radiation Oncology: ctro.science/article/S2405-…

#radonc #sbrt

The GETUG group tried to harmonize our SBRT protocols for bone metastases for our clinical trials on #prostatecancer , #bladdercancer or #kidneycancer .

Results of the Delphi consensus are published #openaccess in ctRO Clinical & Translational Radiation Oncology: doi.org/10.1016/j.ctro…

#radonc

Should Prostatectomy be used in Patients with Oligometastatic Hormone-sensitive Prostate Cancer? Not yet.

Andrew Vickers and I discuss Dai's prostatectomy randomized trial (published European Urology Oncology European Urology bit.ly/3Ssdrs0)

author's link: authors.elsevier.com/a/1fXCp9Cfv-t-…

Another failure of IO + RT for head neck cancer.

Keynote 412 study of concurrent + adjuvant pembrolizumab negative for EFS primary endpoint.

How do we explain these failures?
1. Patient selection?
2. Timing of IO?
3. Intrinsic coldness of localized tumors?

#hncsm #radonc

Clinical and Translational Radiation Oncology has received its first Impact Factor of 4.739!👏Thank you to all submitting authors and congratulations to the editorial team and editors in chief Pierre Blanchard, MD & Daniel Zips👉 bit.ly/3umF8rG
#Radonc #Oncology #OpenAccess

Nat Lester-Coll, MD Mudit Chowdhary, MD Henning Willers, MD Erin Gillespie, MD MPH James Bates Clinical & Translational Radiation Oncology ESTRO Cihan Gani Oncology Advance @ELS_Oncology Pierluigi Bonomo Michael Baumann, MD Radiotherapy & Oncology Hina Saeed, MD C. Jillian Tsai, MD, PhD Usually the IF is around 2/3 of the Citescore (our citescore is 6.8).

Getting IF was major achievement for Clinical & Translational Radiation Oncology

But fully agree with Sue Yom. IF is a poor indicator of journal quality. Our goal is to improve #radonc science dissemination. #openaccess

BIG NEWS: ctRO just got its first impact factor, and it is 4.739.🍾

We at Clinical & Translational Radiation Oncology ESTRO are extremely proud, and thank all the authors, reviewers & board members who trusted us since the beginning.

& submit your #radonc #openaccess papers to ctro.science!

New AUA/ASTRO Amer. Urol. Assn. ASTRO Localized #prostatecancer guidelines.

Cc GETUG

Clinical & Translational Radiation Oncology editorial board meeting at #ESTRO2022 .

With the impact factor coming this June, lots of initiatives to be developed. Exciting!

Submit your papers to ctRO.science

#radonc #OpenAccess cc ESTRO

And it is all #openaccess at Clinical & Translational Radiation Oncology!

By the way, ctRO, the clinical & translational #openaccess sister journal to ESTRO’s Radiotherapy & Oncology will GET ITS FIRST IMPACT FACTOR THIS YEAR!

Stay tuned. #radonc

Programme Highlights not to be missed during #ESTRO2022 !
Check out the full programme👉bit.ly/3APZeNf
#Radonc #Radiotherapy #RadiationOncology

ADT + Abi + DOC new SOC for high volume mHSPC #prostatecancer ?

Results of PEACE 1 trial published The Lancet here: sciencedirect.com/science/articl…

Improvements in OS and rPFS over ADT + DOC

Results will for sure be discussed Advanced Prostate Cancer Consensus Conference OncoAlert

h/t Supiot Stéphane.

#pcsm

Submit to ctRO!

ctRO.science

Cc ESTRO